Assessing the Efficacy of Cefepime-Taniborbactam Combo in Complicated Urinary Tract Infections
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 1st, 2024
|
Urinary tract infection (UTI) is a prevalent illness that can be successfully addressed with beta-lactam antibiotics like cefepime, a fourth-generation cephalosporin. Nonetheless, significant resistance has emerged against these antimicrobial agents, particularly in the form of beta-lactamase. Taniborbactam, a novel beta-lactamase inhibitor, has recently undergone evaluation in combination with cefepime for the treatment of UTIs in a recent study.
The phase 3 clinical trial involved 661 hospitalized patients diagnosed with complicated urinary tract infection (UTI) and acute pyelonephritis. Participants were randomly allocated to receive either the novel combination of 2.0 g Cefepime and 0.5 g Taniborbactam or the standard meropenem regimen. Both treatments were administered intravenously every 8 hours for a duration of 7 days. After a 3-week follow-up period, researchers determined that microbiological clearance was achieved in 71% of patients treated with the combination of 2.0 g Cefepime and 0.5 g Taniborbactam, significantly surpassing the 58% success rate observed in those receiving Meropenem. The superior efficacy of the combination was evident across various Enterobacteriales bacterial species and also in Pseudomonas aeruginosa infections.
The phase 3 clinical trial involved 661 hospitalized patients diagnosed with complicated urinary tract infection (UTI) and acute pyelonephritis. Participants were randomly allocated to receive either the novel combination of 2.0 g Cefepime and 0.5 g Taniborbactam or the standard meropenem regimen. Both treatments were administered intravenously every 8 hours for a duration of 7 days. After a 3-week follow-up period, researchers determined that microbiological clearance was achieved in 71% of patients treated with the combination of 2.0 g Cefepime and 0.5 g Taniborbactam, significantly surpassing the 58% success rate observed in those receiving Meropenem. The superior efficacy of the combination was evident across various Enterobacteriales bacterial species and also in Pseudomonas aeruginosa infections.